Senzime AB (publ) (STO:SEZI)

Market Cap	1.04B
Revenue (ttm)	80.64M
Net Income (ttm)	-126.40M
Shares Out	157.22M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,141
Average Volume	728,111
Open	6.64
Previous Close	6.60
Day's Range	6.56 - 6.77
52-Week Range	3.60 - 9.60
Beta	0.57
RSI	55.10
Earnings Date	Jul 18, 2025

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It provides TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. The company has a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 54
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2024, Senzime AB's revenue was 58.48 million, an increase of 63.55% compared to the previous year's 35.75 million. Losses were -118.73 million, -11.50% less than in 2023.